StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officer

Experienced Biotech Executive to Lead Company’s Next Stage of Growth

Durham, N.C., January 3, 2019 – StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board.

Dr Shah’s career in the pharmaceutical and biotechnology industry spans 20 years and includes multiple roles as CEO, company founder, board member and strategic advisor. Prior Chief Executive positions include ARMGO Pharma, a company advancing treatments for debilitating cardiac and rare muscle diseases, Ezose Sciences, a high-throughput glycomics platform company, and Shionogi Inc., the US pharmaceutical business of Shionogi & Co, Ltd. At Shionogi, Dr Shah launched the company’s initial presence in the US, growing the organization from a small team focused on advancing a single clinical stage program, to a fully integrated clinical development and commercial stage entity with sales of $400 million. Dr Shah began his career as a consultant with McKinsey & Company, where he advised pharmaceutical and biotech clients on a wide range of R&D, commercial and corporate strategy matters. Dr. Shah holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University and Bachelor of Arts degrees in Mathematics, Biochemistry and Integrated Science from Northwestern University.

“We welcome Sapan to StrideBio,” stated Clay Thorp, General Partner, Hatteras Venture Partners. “His history of founding and building successful organizations comes at an important time in the company’s evolution, as it advances multiple preclinical programs into the clinic and establishes its own in-house GMP manufacturing capabilities. In addition, Sapan’s prior experience in building and leading a rare diseases company will be invaluable as StrideBio strengthens its ties with key stakeholders including the patient community.”

“I would like to thank the Founders and the rest of the Board for their confidence in me to continue building StrideBio into a leading, clinically focused gene therapy company,” stated Dr Shah. “StrideBio has all the key elements for success including a differentiated technology platform that can generate novel AAV capsids with truly unique profiles, along with in-house manufacturing capabilities to support clinical development and commercialization. In the year ahead, we look forward to advancing multiple preclinical programs towards clinical trials and executing a focused set of strategic partnerships. I look forward to working with the Board to ensure the continued growth and success of StrideBio.”

About StrideBio, Inc.
StrideBio, Inc is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) therapies for rare diseases. Our STRucture Inspired DESign approach holds the potential to generate unique AAV capsids with improved characteristics including potency, tropism, and ability to evade pre-existing antibodies. This powerful new approach has broad application, enabling gene addition, gene silencing and gene editing modalities for a wide
range of diseases, including rare genetic diseases. StrideBio is headquartered in Durham, NC. For more information, please visit www.stridebio.com.

About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Durham, NC with a focus on seed and early stage healthcare investing. The firm focuses on biopharmaceutical, healthcare IT, medical device, and diagnostic opportunities. Hatteras has approximately $450 million under management in five venture capital funds. The firm is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation. To learn more about Hatteras Venture Partners, please visit www.hatterasvp.com.

STRIDEBIO CONTACT:
Richard E. T. Smith, PhD
609-865-0693
r.smith@stridebio.com